Zacks Investment Research
19 Jun 2026, 09:31 UTC · 20w ago
Impact · against what's priced in
Biodesix is seeing positive momentum driven by a price target increase to $27.00 and expectations of 30.4% year-over-year revenue growth. While widening quarterly losses persist, the upward revision in EPS estimates and top-line growth provide a fundamental catalyst for the stock.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Canaccord Genuity raised its price target for Biodesix (BDSX) from $22.00 to $27.00 while maintaining a 'Buy' rating.
More positive than 93% of claims this week
Biodesix is expected to report revenue growth of 30.4% year-over-year for its upcoming quarterly report.
So whatStrong top-line growth projections are a fundamental driver for valuation increases in growth-oriented medical services companies.
Continue reading
5 related stories
The stock is reacting to a price target increase to $27.00 and strong revenue growth projections of 30.4%, which outweigh the expected increase in quarterly losses to $0.85 per share.
Read from the article alone
No priced-in read yet
The article mentions GoodRx only as a peer in the medical services industry; it provides no company-specific news or catalysts.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 76% of claims this week
The consensus EPS estimate for Biodesix has been revised 4% higher over the last 30 days.
More positive than 62% of claims this week
Biodesix is expected to post a quarterly loss of $0.85 per share, a 46.9% increase in loss year-over-year.
More negative than 70% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
24m ago
—
No price for GDRX right now — the quote feed didn't answer.
GDRX chart →—
No price for BDSX right now — the quote feed didn't answer.
BDSX chart →
